Compare AIOT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | DSGN |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.8M | 819.6M |
| IPO Year | N/A | 2021 |
| Metric | AIOT | DSGN |
|---|---|---|
| Price | $3.27 | $14.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.33 | ★ $15.25 |
| AVG Volume (30 Days) | ★ 1.3M | 553.4K |
| Earning Date | 06-15-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.46 | N/A |
| Revenue Next Year | $9.01 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $3.31 |
| 52 Week High | $5.98 | $17.25 |
| Indicator | AIOT | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 53.55 |
| Support Level | $2.82 | $9.25 |
| Resistance Level | $3.39 | $17.25 |
| Average True Range (ATR) | 0.14 | 1.23 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 56.32 | 30.36 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.